Analyst Price Targets — TVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 14, 2026 11:48 am | Vamil Divan | Guggenheim | $49.00 | $28.39 | StreetInsider | Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX) |
| September 10, 2025 2:48 pm | Maury Raycroft | Jefferies | $35.00 | $27.31 | TheFly | AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies |
| October 31, 2024 8:21 pm | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI |
| October 21, 2024 5:38 am | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | StreetInsider | Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight |
| October 10, 2024 9:24 am | Liisa Bayko | Evercore ISI | $30.00 | $18.07 | TheFly | Travere Therapeutics price target raised to $30 from $12 at Evercore ISI |
| October 9, 2024 6:57 am | Jason Zemansky | Bank of America Securities | $20.00 | $15.21 | TheFly | Travere Therapeutics price target raised to $20 from $18 at BofA |
| October 1, 2024 5:38 am | Carter Gould | Barclays | $18.00 | $13.99 | TheFly | Travere Therapeutics price target raised to $18 from $14 at Barclays |
| September 27, 2024 6:42 am | Vamil Divan | Guggenheim | $23.00 | $15.04 | TheFly | Travere Therapeutics price target lowered to $23 from $25 at Guggenheim |
| September 27, 2024 6:10 am | Ed Arce | H.C. Wainwright | $18.00 | $15.04 | TheFly | Travere Therapeutics price target lowered to $18 from $23 at H.C. Wainwright |
| September 27, 2024 5:59 am | Greg Harrison | Bank of America Securities | $18.00 | $14.01 | StreetInsider | Travere Therapeutics (TVTX) PT Lowered to $18 at BofA Securities |
Latest News for TVTX
Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost…
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) shares dropped 5.4% on Friday. The company traded as low as $27.97 and last traded at $27.7250. Approximately 190,670 shares changed hands during trading, a decline of 92% from the average daily volume of 2,425,504 shares. The stock had previously closed at $29.30. Wall Street Analyst
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVTX.
U.S. House Trading
No House trades found for TVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.